CNN Calls Out 'Cataract Risk' in HOPE-3

ACC Conference Reporter

ACC.16 | CHICAGO — Two days after HOPE-3 results were lauded as proof of statins' safety and efficacy, CNN quotes a Tweet from @Eric Topol: "first randomized trial to show risk of cataracts w/statins." MedPage Today asks Deepak Bhatt, Steven Nissen, C. Michael Valentine, and Alfred Bove to put this risk into perspective. Read More >>>

Keywords: ACC Annual Scientific Session

< Back to Listings